Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00507260
Other study ID # 2006-0515
Secondary ID
Status Completed
Phase N/A
First received July 24, 2007
Last updated December 23, 2014
Start date September 2006
Est. completion date December 2014

Study information

Verified date December 2014
Source M.D. Anderson Cancer Center
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

Primary Objective:

1. To use the results from this pilot study to estimate the effect size of the nutritional intervention on fatigue and caloric intake.

Secondary Objectives:

1. To apply nutritional assessment tools for early detection of patients at risk for malnutrition.

2. To examine the feasibility of conducting this intervention study.

3. To describe cancer-related fatigue patterns among BMT patients at multiple time points during ambulatory visits.

4. To evaluate the effects of a nutritional intervention for post-allogeneic BMT recipients on adequacy of caloric intake in order to improve cancer-related fatigue scores.


Description:

Recipients of an allogeneic BMT often experience fatigue as a side effect due to several factors, including high-dose chemotherapy and/or radiation therapy as well as stress from everyday activities that increase fatigue. In addition, after transplantation, the patient's ability to maintain regular nutritional needs (usually due to the unique diet that is required to help increase marrow function) is affected, which further increases fatigue levels. Researchers want to use information learned in this study to find out if nutritional intervention can help decrease fatigue levels and increase caloric intake.

Participating in this study involves routine visits to M. D. Anderson at the ambulatory treatment center. Before you can start on this study, you will be asked about any allergies you may have. You will also be asked some questions about your caregivers, such as how many caregivers you have, whether your caregiver will be able to attend the nutrition class with you, and whether the caregiver will record the food intake information. You will be asked these questions to help the study researcher decide if you are eligible to take part in this study. It should take about 30 minutes to collect this data. Your caregiver will be present while this data is being collected. You will be asked to fill out questionnaires about your medical history, personal demographics (such as your name, age, race, and gender), and fatigue levels. These questionnaires should take about less than 1 hour to complete. The study researcher will collect these questionnaires and put them in an envelope with a code ID number on the front cover, instead of your name or other personal information.

A dietitian will then set-up an appointment (within 3 days after your first visit to the ambulatory clinics) for a baseline test called indirect calorimetry. This test will be performed in your treatment room in the ambulatory treatment clinic to find out how many calories you need to have on a daily basis. For this test, you will be asked to sit quietly in your treatment room and breathe through a mouth piece with a nose clip on your nose for 10 minutes. This test will use a machine to collect the air that you breathe in (inhalation) and out (exhalation). The machine will use the information from your breathing to calculate how many calories you will need to intake each day. This entire process should take about 1 hour to complete. You will be given recommended levels of dietary caloric intake and your schedule for study activities within the first week of enrolling in this study. After this test, you will be randomized (as in the toss of a coin) to a group.

There will be 2 groups in this study. There will be about 6 participants in each group. If you are found to be eligible and you agree to take part in this study, you will be asked to draw a sealed envelope from a bag, which will show which study group you will be in. You will be allowed to draw only 1 envelope from the bag. You will have an equal chance of being assigned to either group.

Participants in 1 group will be given standard care (for the next 42 days) for allogeneic BMT at the ambulatory center. Participants in the other group will be given standard care (for the next 45 days) for allogeneic BMT at the ambulatory center as well as nutritional assessment and intervention. If your envelope has a label that says "standard," you will receive standard care only. If your envelope has a label that says "intervention," you will receive standard care as well as nutritional assessment and intervention.

During the first week on this study, you and your caregiver will receive training from the dietitian about putting information in a food record, which will include your name and the amount and kind of food and drink you intake from the time you get out of bed to the time you go to bed. On Days 7, 21, and 35 (Weeks 1, 3, and 5), the study researcher will remind you and your caregiver to start this food record and give you the recording sheets. You have to turn in 3 daily food records for the specified weeks. If you have some days off from the ambulatory center visits during that week, the study researcher would like you to complete a one-day food record on your day off as part of the 3 daily records.

If you have a different caregiver on any one of the weeks, the dietitian will train the new caregiver to record food and drinks on these days. The study researcher will collect the food records and give you a fatigue questionnaire on Days 14, 28, and 42. It should take about 30 minutes to complete. If you are not scheduled for a clinic visit on these specified days, the study researcher will meet with you on the first visit following these dates.

If you are in the standard care group, you will receive an indirect calorimetry test at the beginning of study, and you will submit 3-day food records every 2 weeks. You will not receive the results from these food records. Your health care provider may refer you to see a dietitian at any time during this study as part of your standard care. If at any time your caloric intake is considered to be 50% or less of your expected intake, your regular doctor will be notified.

If you are in the intervention group, the results from these food records will be given to you by a dietitian within 3 days after the collection of food records (Days 17, 31, and 45). You will receive these results in person with a dietitian consultant. You will be able to discuss any issues related to food intake (such as food choices, food options, problems related to meal preparation, and how to increase calories or nutrients) so that you might be able to bring up the caloric intake to good level.

You will be taken off this study if you develop a condition called gastrointestinal graft versus host disease, major organ failure (such as heart, kidney, or liver), or any intolerable side effects from the standard care treatment you are on.

This is an investigational study. Up to 12 patients will take part in this pilot study. All will be enrolled at M. D. Anderson.


Recruitment information / eligibility

Status Completed
Enrollment 10
Est. completion date December 2014
Est. primary completion date December 2014
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Subject has been diagnosed with cancer (leukemia or lymphoma).

2. Age 18 years or older

3. Subject has received their allogeneic BMT, fully ablative transplants, from either related or unrelated donors in the past 40 days

4. Subject can read, write, speak, and understand English

5. Subject has a caregiver (family member or friend) to keep the food diary record.

6. Subject voluntarily agrees and signs informed consent prior to participate in this study.

7. Subject is oriented to time, place, and person.

Exclusion Criteria:

1. Subject has major organ failure such as kidney, heart, or liver failure.

2. Subject has allergies to latex preventing use of the mouthpiece during indirect calorimetry testing.

3. Subject has been scheduled to withhold oral intake or parenteral nutrition support for more than 4 days during the week of dietary record (week 2, 4, and 6)

4. Subject has a diagnosis of gastro-intestinal graft versus host disease (GI-GVHD).

5. Subject has pre-transplant pulmonary function tests (PFTs) with force vital capacity (FVC) or forced expiratory volume in one second (FEV1) or diffusing capacity of the lung for carbon monoxide (DLCO) < 65% of predicted value.

6. Subject who is physically unable to complete the indirect calorimetry or who refuses calorimetry or who cannot understand the instructions.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Behavioral:
Food Record
A record of the amount and kind of food and drink you intake will be completed.
Other:
Nutritional Consults
Meeting with a dietician consultant regarding issues related to food intake. Participants will also receive the results from the food records.

Locations

Country Name City State
United States University of Texas MD Anderson Cancer Center Houston Texas

Sponsors (1)

Lead Sponsor Collaborator
M.D. Anderson Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Patient Fatigue Scores <Brief Fatigue Inventory (BFI)> BFI at study day 0, 14, 28, and 42 No
See also
  Status Clinical Trial Phase
Recruiting NCT05540340 - A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant Phase 1
Completed NCT01947140 - Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies Phase 1/Phase 2
Completed NCT00001512 - Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines Phase 1
Recruiting NCT05618041 - The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies N/A
Completed NCT01410630 - FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma
Active, not recruiting NCT04270266 - Mind-Body Medicine for the Improvement of Quality of Life in Adolescents and Young Adults Coping With Lymphoma N/A
Terminated NCT00801931 - Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders Phase 1/Phase 2
Completed NCT01949883 - A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma Phase 1
Completed NCT01682226 - Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies Phase 2
Completed NCT00003270 - Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer Phase 2
Recruiting NCT05019976 - Radiation Dose Study for Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma N/A
Recruiting NCT04904588 - HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide Phase 2
Completed NCT04434937 - Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213) Phase 2
Completed NCT01855750 - A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma Phase 3
Terminated NCT00788125 - Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Phase 1/Phase 2
Terminated NCT00775268 - 18F- Fluorothymidine to Evaluate Treatment Response in Lymphoma Phase 1/Phase 2
Active, not recruiting NCT04188678 - Resiliency in Older Adults Undergoing Bone Marrow Transplant N/A
Terminated NCT00014560 - Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia Phase 1
Recruiting NCT04977024 - SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer Phase 2
Active, not recruiting NCT03936465 - Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer Phase 1